Thomas Yeung

Thomas Yeung

CFA, InvestorPlace Markets Analyst

Expertise: Fundamental Analysis, Quant-Based Investing, Tax Analysis

Education: BA, Economics, Princeton University

Awards & Accomplishments: CFA Charterholder, IRS Enrolled Agent

Thomas Yeung, CFA, is a Market Analyst at InvestorPlace.com, where he helps investors navigate the world of finance with one of the most powerful tools available: knowledge. Tom brings over a decade of experience in company, commodity and industry analysis.

He is the current editor of the Omnia Portfolios, the highest-tier subscription at InvestorPlace and the former editor of Tom Yeung’s Profit & Protection, a free e-letter about investing to profit in good times and protecting gains during the bad.

Tom started his investment career at Harding Loevner, a $40 billion asset management firm. Today, he works with InvestorPlace.com to help individuals and families identify great investments.

Tom holds a BA in Economics from Princeton University, where he graduated with high honors. He is a CFA® Charterholder and also a FINRA Registered Investment Adviser.

Recent Articles

Argo Blockchain Could Reach $40. Why 6,000% Gains Might Be Just the Start

By Thomas Yeung, CFA, InvestorPlace Markets Analyst

Argo Blockchain has stunned investors with its 6,000% return since October. Here's why the company might not be finished yet.

Winners and Losers From Texas’ Deep Freeze: Natural Gas, Chips and More

By Thomas Yeung, CFA, InvestorPlace Markets Analyst

Who are the winners and losers from Texas' climate disaster? While the jury is still out on Biden's Green New Deal, natural gas will win.

Attention Reddit: Expiring PLTR Stock Lockups Provides a Second Buying Opportunity

By Thomas Yeung, CFA, InvestorPlace Markets Analyst

On Thursday, 80% of PLTR stock suddenly became free to trade. Now that shares are down 35% from their peaks, should Reddit users buy?

NVAX Stock Is the Most Undervalued Vaccine Maker for Endemic Covid-19

By Thomas Yeung, CFA, InvestorPlace Markets Analyst

As Covid-19 becomes endemic, rich governments will turn to Novavax to vaccinate people in developing economies. NVAX stock will benefit.

EH Stock: 5 Things for Investors to Know as EHang Refutes ‘Sham’ Claims

By Thomas Yeung, CFA, InvestorPlace Markets Analyst

On Tuesday, Wolfpack Research issued a scathing analysis of EH stock. Here's what investors need to know for what comes next.

Load More